Tracing the History of the Human Translocator Protein to Recent Neurodegenerative and Psychiatric Imaging.
Olivia M DownerRachel E G MarcusNicole R ZürcherJacob M HookerPublished in: ACS chemical neuroscience (2020)
The human 18 kDa translocator protein (TSPO) has been widely used as a measure of glial activation in health and disease. With the continuous progress of radiotracers with increased affinity and selectivity, associations between TSPO expression, disease severity, and progression have been examined, particularly in neurodegenerative disorders such as multiple sclerosis (MS), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). However, findings in psychiatric disorders have prompted reassessment of the interpretation of regional TSPO expression differences in the brain, specifically with respect to potential neuroinflammatory components. This "mini" Review aims to guide readers through the complexity of TSPO imaging research by identifying the successes, challenges, and promising new directions of the field. We will provide a brief history of how TSPO imaging has evolved over the last three decades and present lessons learned in the context of neurodegenerative and psychiatric disorders.
Keyphrases
- amyotrophic lateral sclerosis
- multiple sclerosis
- pet imaging
- high resolution
- endothelial cells
- poor prognosis
- binding protein
- healthcare
- mental health
- public health
- mass spectrometry
- ms ms
- white matter
- induced pluripotent stem cells
- pluripotent stem cells
- computed tomography
- amino acid
- spinal cord injury
- human health
- climate change
- risk assessment
- photodynamic therapy
- neuropathic pain
- blood brain barrier
- heat shock protein
- positron emission tomography
- capillary electrophoresis